SCHEMBL25843145

SCHEMBL25843145

NOC1=NC(=O)C([C@H]2OC(COP(=O)(O)O)C(O)C2O)C=C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 3/20 0.46
ATIC P31939 1/20 0.39
P2RY2 P41231 3/20 0.38
LDHA P00338 2/20 0.38
P2RY6 Q15077 1/20 0.38
CA5A P35218 1/20 0.38
DNPH1 O43598 2/20 0.37
PRKAB2 O43741 1/20 0.37
TRPM2 O94759 1/20 0.37
ADRB2 P07550 1/20 0.37
SRC P12931 1/20 0.37
ADORA1 P30542 1/20 0.37
P2RY1 P47900 1/20 0.37
PRKAG1 P54619 1/20 0.37
PRKAA2 P54646 1/20 0.37
PDE4D Q08499 1/20 0.37
KCNH2 Q12809 1/20 0.37
PRKAA1 Q13131 1/20 0.37
PDE3A Q14432 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18118154 0.76 FBP1 (0.46) FBP1ATICP2RY2LDHAP2RY6
SCHEMBL18350031 0.76 FBP1 (0.46) FBP1ATICP2RY2LDHAP2RY6
SCHEMBL18118157 0.76 FBP1 (0.46) FBP1ATICP2RY2LDHAP2RY6
SCHEMBL18350026 0.76 FBP1 (0.46) FBP1ATICP2RY2LDHAP2RY6
SCHEMBL15305518 0.76 FBP1 (0.46) FBP1ATICP2RY2LDHAP2RY6
SCHEMBL25843161 0.74 POLB (0.38) P2RY2P2RY6
SCHEMBL15722784 0.73 FBP1 (0.48) FBP1ATICP2RY2P2RY6DNPH1
SCHEMBL18963500 0.70 TRPM2 (0.38) P2RY2P2RY6TRPM2SRCP2RY1
SCHEMBL18963501 0.70 TRPM2 (0.38) P2RY2P2RY6TRPM2SRCP2RY1
SCHEMBL17001181 0.70 TRPM2 (0.38) P2RY2P2RY6TRPM2SRCP2RY1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219994-A1 MODIFIED NUCLEOSIDE AND SYNTHESIS METHOD THEREFOR Stemirna Therapeutics Co., Ltd. (CN) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219994-A1 MODIFIED NUCLEOSIDE AND SYNTHESIS METHOD THEREFOR RNMT, RNGTT, BCDIN3D FBP1 965/4885ATIC 45/4885P2RY2 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.